Market News

Manchester United Plc (MANU) Shareholder Lindsell Train LTD Boosted Its Stake by $3.49 Million; Ra Capital Management Trimmed Its Position in Dicerna Pharmaceuticals (DRNA) by $9.29 Million

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Lindsell Train Ltd increased its stake in Manchester United Plc (MANU) by 2.37% based on its latest 2018Q1 regulatory filing with the SEC. Lindsell Train Ltd bought 183,624 shares as the company’s stock rose 6.85% while stock markets declined. The institutional investor held 7.92 million shares of the services-misc. amusement & recreation company at the end of 2018Q1, valued at $152.08 million, up from 7.74 million at the end of the previous reported quarter. Lindsell Train Ltd who had been investing in Manchester United Plc for a number of months, seems to be bullish on the $3.57B market cap company. The stock decreased 0.46% or $0.1 during the last trading session, reaching $21.75. About 52,280 shares traded or 81.46% up from the average. Manchester United plc (NYSE:MANU) has risen 18.26% since June 14, 2017 and is uptrending. It has outperformed by 5.69% the S&P500. Some Historical MANU News: 19/05/2018 – Soccer-Chelsea beat Manchester Utd 1-0 to win FA Cup; 06/04/2018 – Arab News: BREAKING: Paul Pogba’s agent asked Manchester City if they would be interested in signing the restless Manchester U; 09/05/2018 – Independent.ie: BREAKING: Sir Alex Ferguson ‘no longer needs intensive care and will continue rehabilitation as an inpatient’; 22/03/2018 – Soccer-lbrahimovic set to leave Manchester Utd for LA Galaxy -reports; 17/05/2018 – MANU SEES FY ADJ EBITDA GBP175M TO GBP185M, EST. GBP184.5M; 05/05/2018 – Arab News: #BREAKING: #ManchesterUnited says former manager #AlexFerguson has undergone emergency surgery for brain hemorrhage; 07/05/2018 – NTT Communications Expands Global IP Network with New Point-of-Presence in Manchester, United Kingdom; 13/03/2018 Soccer-United crash out after Sevilla’s Ben Yedder strikes twice

Peter Kolchinsky decreased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 20.78% based on its latest 2018Q1 regulatory filing with the SEC. Ra Capital Management Llc sold 1.03M shares as the company’s stock rose 0.36% while stock markets declined. The hedge fund run by Peter Kolchinsky held 3.93M shares of the health care company at the end of 2018Q1, valued at $37.60M, down from 4.97 million at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be less bullish one the $680.34 million market cap company. The stock increased 3.21% or $0.4 during the last trading session, reaching $12.88. About 293,048 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since June 14, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: 20/04/2018 – DICERNA PHARMACEUTICALS – SETTLEMENT ALLOWS CO TO ADVANCE ALL KEY, PLANNED PIPELINE PROGRAMS; 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 14/05/2018 – DICERNA PHARMACEUTICALS INC – BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 20/04/2018 – Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation; 20/04/2018 – DICERNA PHARMACEUTICALS – SETTLEMENT EXCLUDES ANY AMOUNTS RECEIVED BY DICERNA FROM ITS EXISTING COLLABORATION WITH BOEHRINGER-INGELHEIM; 20/04/2018 – Biotech companies Alnylam, Dicerna settle trade secrets case; 17/04/2018 – STAT Plus: Trade secrets battle between Alnylam, Dicerna is just one of many

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. SunTrust initiated Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Monday, February 5. SunTrust has “Buy” rating and $13.0 target. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Hold” rating by FBR Capital on Tuesday, March 27. The rating was downgraded by H.C. Wainwright on Friday, March 23 to “Neutral”. The firm earned “Buy” rating on Wednesday, November 11 by Stifel Nicolaus. The firm earned “Neutral” rating on Monday, August 15 by Chardan Capital Markets. The firm earned “Buy” rating on Monday, December 12 by H.C. Wainwright. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 16. The stock has “Buy” rating by Cowen & Co on Tuesday, July 18. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, August 10 report. H.C. Wainwright maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Friday, August 11. H.C. Wainwright has “Buy” rating and $600 target.

Another recent and important Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news was published by Nasdaq.com which published an article titled: “Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR …” on May 18, 2018.

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on August, 9. They expect $-0.42 EPS, up 63.48% or $0.73 from last year’s $-1.15 per share. After $-0.30 actual EPS reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.

Since December 18, 2017, it had 1 insider buy, and 4 insider sales for $1.57 million activity. Weissman James B had sold 8,965 shares worth $116,545 on Friday, April 20. $2.00M worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares were bought by Bain Capital Life Sciences Investors – LLC.

Investors sentiment decreased to 2.44 in Q1 2018. Its down 0.56, from 3 in 2017Q4. It turned negative, as 3 investors sold DRNA shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. Manufacturers Life Company The has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1,825 shares. California-based Eam Invsts Limited Co has invested 0.08% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Price T Rowe Associate Md has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 83,594 shares. Morgan Stanley holds 14,362 shares or 0% of its portfolio. 18,244 were accumulated by Dimensional Fund Advisors Limited Partnership. Deutsche Bancshares Ag holds 0% or 2,200 shares in its portfolio. Cubist Systematic Strategies Ltd Liability Com holds 0.01% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 10,665 shares. Birchview Lp reported 0.28% stake. Spark Invest Ltd Liability Company has invested 0.09% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Jpmorgan Chase And holds 120,948 shares or 0% of its portfolio. Caxton Corp, New Jersey-based fund reported 13,074 shares. Acadian Asset Mgmt Limited Liability has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Panagora Asset, a Massachusetts-based fund reported 7,533 shares. The New York-based Jane Street Grp Limited Co has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Quantitative Systematic Strategies Limited Liability Com reported 11,794 shares.

Investors sentiment decreased to 0.74 in Q1 2018. Its down 1.64, from 2.38 in 2017Q4. It is negative, as 6 investors sold MANU shares while 17 reduced holdings. 8 funds opened positions while 9 raised stakes. 34.55 million shares or 0.49% less from 34.72 million shares in 2017Q4 were reported. Spark Invest Ltd Liability holds 0.07% of its portfolio in Manchester United plc (NYSE:MANU) for 54,300 shares. Royal Bank & Trust Of Canada stated it has 2,818 shares or 0% of all its holdings. 26,226 were reported by Goldman Sachs. Moreover, Thompson Davis And Company Inc has 0.07% invested in Manchester United plc (NYSE:MANU) for 1,299 shares. National Bank Of America De owns 41,106 shares. Deutsche Bancshares Ag reported 35,382 shares. 47,561 are held by Roundview Lc. Jpmorgan Chase & Co owns 9,270 shares. Wells Fargo Com Mn reported 0% in Manchester United plc (NYSE:MANU). Bamco New York reported 14.11 million shares or 1.25% of all its holdings. Us Savings Bank De has invested 0% in Manchester United plc (NYSE:MANU). Assetmark owns 0% invested in Manchester United plc (NYSE:MANU) for 4 shares. Clark Estates Inc Ny reported 87,498 shares. Renaissance Technologies Ltd Liability Corporation holds 0.01% or 598,615 shares in its portfolio. Pdt Prtn owns 12,000 shares.

Among 6 analysts covering Manchester United Ltd. (NYSE:MANU), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Manchester United Ltd. had 15 analyst reports since September 18, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Thursday, November 16. The rating was maintained by Jefferies on Friday, September 22 with “Buy”. Credit Suisse maintained Manchester United plc (NYSE:MANU) on Tuesday, March 15 with “Outperform” rating. The firm earned “Hold” rating on Tuesday, May 22 by Deutsche Bank. The stock has “Buy” rating by Jefferies on Monday, June 5. Jefferies maintained Manchester United plc (NYSE:MANU) on Monday, August 14 with “Buy” rating. As per Tuesday, August 16, the company rating was maintained by Jefferies. Jefferies maintained the stock with “Buy” rating in Monday, September 18 report. The firm has “Buy” rating given on Monday, October 17 by Gabelli. Jefferies maintained the stock with “Buy” rating in Friday, September 18 report.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *